IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

GUIDETTI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.585
NA - Nord America 4.837
AS - Asia 4.682
Continente sconosciuto - Info sul continente non disponibili 461
SA - Sud America 449
AF - Africa 90
OC - Oceania 79
Totale 16.183
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.613
CN - Cina 1.633
IT - Italia 1.224
DE - Germania 1.221
SG - Singapore 1.145
GB - Regno Unito 1.018
RU - Federazione Russa 337
SE - Svezia 337
BR - Brasile 317
HK - Hong Kong 315
BD - Bangladesh 308
VN - Vietnam 282
FR - Francia 275
JP - Giappone 253
IN - India 226
ES - Italia 220
FI - Finlandia 176
CA - Canada 131
NL - Olanda 126
IE - Irlanda 119
TR - Turchia 113
CH - Svizzera 102
UA - Ucraina 100
KR - Corea 82
AU - Australia 75
ID - Indonesia 68
AT - Austria 52
MX - Messico 49
TH - Thailandia 48
BE - Belgio 46
GR - Grecia 43
AR - Argentina 41
PL - Polonia 40
DK - Danimarca 37
CO - Colombia 29
CI - Costa d'Avorio 27
TW - Taiwan 23
CZ - Repubblica Ceca 22
PE - Perù 21
EU - Europa 20
IR - Iran 20
SA - Arabia Saudita 19
LB - Libano 17
PT - Portogallo 17
IQ - Iraq 15
PH - Filippine 15
MA - Marocco 12
UZ - Uzbekistan 12
ZA - Sudafrica 12
IL - Israele 11
JO - Giordania 11
MY - Malesia 11
EC - Ecuador 10
PK - Pakistan 10
VE - Venezuela 10
AZ - Azerbaigian 9
CR - Costa Rica 9
BA - Bosnia-Erzegovina 8
EG - Egitto 8
AE - Emirati Arabi Uniti 7
CL - Cile 7
GT - Guatemala 7
HR - Croazia 7
EE - Estonia 6
LU - Lussemburgo 6
SC - Seychelles 6
TN - Tunisia 6
TT - Trinidad e Tobago 6
BG - Bulgaria 5
HU - Ungheria 5
JM - Giamaica 5
KE - Kenya 5
LV - Lettonia 5
NO - Norvegia 5
NP - Nepal 5
PS - Palestinian Territory 5
PY - Paraguay 5
SI - Slovenia 5
UY - Uruguay 5
DZ - Algeria 4
KZ - Kazakistan 4
LT - Lituania 4
NZ - Nuova Zelanda 4
AL - Albania 3
AM - Armenia 3
BO - Bolivia 3
QA - Qatar 3
RO - Romania 3
RS - Serbia 3
BH - Bahrain 2
BS - Bahamas 2
ET - Etiopia 2
GA - Gabon 2
GH - Ghana 2
GP - Guadalupe 2
HN - Honduras 2
KW - Kuwait 2
MK - Macedonia 2
NI - Nicaragua 2
PA - Panama 2
Totale 15.719
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 823
Southend 799
Singapore 666
Ashburn 538
Milan 387
Chandler 280
Hong Kong 273
Beijing 272
San Jose 241
Council Bluffs 181
Dallas 156
Santa Clara 156
Seattle 142
Wilmington 137
Helsinki 127
Fairfield 124
Los Angeles 120
Dublin 118
New York 109
Princeton 99
Hefei 95
Hangzhou 90
Shanghai 84
Ann Arbor 77
Houston 77
Moscow 76
Nanjing 76
Tokyo 76
Bengaluru 75
Dearborn 74
Ho Chi Minh City 74
Guangzhou 71
Jacksonville 68
Hanoi 67
Rome 67
Woodbridge 63
Barcelona 59
Chicago 59
Lauterbourg 58
Buffalo 54
Columbus 53
Jakarta 50
Munich 46
Redwood City 44
Redmond 43
Tianjin 42
São Paulo 41
The Dalles 40
Cambridge 39
Des Moines 36
Serra 36
Vienna 36
Madrid 35
Istanbul 34
Hanover 33
Naples 32
Atlanta 31
Mountain View 31
London 30
Boardman 29
Toronto 29
Abidjan 27
Berlin 27
Lugano 27
Paris 27
Jinan 26
Philadelphia 26
Phoenix 26
Somerville 26
Boston 25
Shenzhen 24
Bogotá 23
Brisbane 23
Nuremberg 23
Nanchang 22
Cangzhou 21
Bangkok 20
Brussels 20
Shenyang 20
Sydney 20
Zhengzhou 20
Bologna 19
Sakarya 19
San Diego 19
Wuhan 19
Andover 18
Athens 18
Southampton 18
Florence 17
Fremont 17
Haiphong 17
Mexico City 17
Montreal 17
Stockholm 17
Washington 17
Zurich 17
Beirut 16
Chengdu 16
Da Nang 16
Fuzhou 16
Totale 8.781
Salva come PNG Salva come JPEG
Nome #
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 2.136
Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside 679
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas 623
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma 573
High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression 419
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) 322
Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients 309
A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy 294
Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome 285
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells 272
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 257
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial 256
Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes 251
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion : an outpatient preparative regimen for autologous hematopoietic cell transplantation 241
Interferon γ enhances the anti-myeloma activity of the fully human anti-HLA-DR monoclonal antibody 1D09C3 238
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 233
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice 227
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a phase I trial in metastatic melanoma 226
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 224
Pomalidomide for the treatment of relapsed and refractory multiple myeloma 218
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34+ cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial 216
SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma 216
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts 215
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from EPICOVIDEHA survey 214
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone (rhGH) 214
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers 213
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 212
Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma : long-term outcomes and graft-versus-host disease-free/relapse-free survival 212
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 210
Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation : Life-threating Features Within the Early Post-engraftment Phase 209
IFN-γ enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 206
Gene Abnormalities in Transplant Associated-Thrombotic Microangiopathy: Comparison between Recipient and Donor's DNA 198
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis 196
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®) 190
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor : an algorithm for the pre-emptive use of plerixafor 188
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases 187
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 185
Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy 181
Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with Defibrotide and recombinant human granulocyte colony-stimulating factor 181
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy : possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. 181
Methodological framework for radiomics applications in Hodgkin’s lymphoma 178
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report 176
Early Serum TARC Reduction Predicts Prognosis in Advanced-Stage Hodgkin Lymphoma Patients Treated with a PET-Adapted Strategy 175
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics 174
Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes? 173
Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma 165
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry 164
High response rate and manageable toxicity with an intensive, short-term chemotherapy program for Burkitt’s lymphoma in adults 162
COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP 160
T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies 159
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 157
Detection of minimal residual disease in hematopoietic progenitor cell harvests : lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma 152
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD 147
Timing of high dose methotrexate CNS prophylaxis in DLBCL : a multicenter international analysis of 1,384 patients 145
Radioimmunotherapy and secondary leukemia : a case report 144
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study 134
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 130
Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma : long-term follow-up 127
Phase II study of sorafenib in patients with relapsed or refractory lymphoma 124
Long-term results of autologous hematopoietic stem-cell transplantation after high-dose 90Y-ibritumomab tiuxetan for patients with poor-risk non-Hodgkin lymphoma not eligible for high-dose BEAM 118
Resistance to proteasome inhibitors in multiple myeloma 109
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022 103
Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF 96
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey 88
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T: an EPICOVIDEHA survey 86
Cytokine secretion associated with the clearance of apoptotic bodies in renal cell carcinoma patients 80
Systemic inflammation and CAR-T specific toxicities as major drivers of non-relapse mortality: analysis from the Italian prospective observational CART-SIE Study 71
Inflammation and lymphoma: Therapeutic implications 65
Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis 59
Efficacy of antibody–drug conjugate brentuximab vedotin in treating Hodgkin’s lymphoma 55
Totale 16.183
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.394
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.394
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.054 0 53 52 47 53 68 69 176 145 104 77 210
2022/20231.550 142 146 111 106 158 225 71 124 148 73 149 97
2023/20242.053 84 103 127 135 274 124 221 213 109 169 234 260
2024/20252.705 176 270 188 226 204 156 144 237 154 207 245 498
2025/20264.670 461 295 429 323 396 323 535 254 548 343 429 334
2026/2027633 252 381 0 0 0 0 0 0 0 0 0 0
Totale 16.183